HCPCS Level II code Q5106 represents injection of epoetin alfa-epbx (Retacrit), a biosimilar erythropoiesis-stimulating agent (ESA), in 1000-unit increments. ESAs play a central role in treating anemia related to chronic conditions and certain therapies, making this code relevant across outpatient and ambulatory care settings where injectable biologics are administered. Nationally, utilization and coverage of biosimilar ESAs affect drug spend, patient access, and contracting strategies for major payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for epoetin alfa-epbx, benchmarks for unit-based billing, common sites of service, and payer coverage patterns. The publication summarizes typical billing practices, relevant policy considerations for biosimilars, and coding nuances specific to HCPCS Level II code Q5106.

The report helps payers, providers, and billing professionals understand where Q5106 fits within ESA therapy workflows, what to expect in outpatient administration settings, and which commercial and federal payers are commonly involved. Data not available in the input is noted where applicable.